(Q38066584)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23231513%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

review article

1 reference

title

Everolimus (RAD001): first systemic treatment for subependymal giant cell astrocytoma associated with tuberous sclerosis complex (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23231513%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference

subependymal giant cell astrocytoma

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23231513%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Katarzyna Kotulska

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23231513%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

author name string

Karen Stein

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23231513%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

language of work or name

English

0 references

publication date

1 December 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23231513%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23231513%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23231513%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23231513%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

page(s)

1515-1523

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23231513%20AND%20SRC:MED&resulttype=core&format=json

Tuberous sclerosis complex: neurological, renal and pulmonary manifestations

20 February 2020

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.146

Tuberous sclerosis complex: advances in diagnosis, genetics, and management.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.146

Tuberous sclerosis complex: tumors and tumorigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.146

Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.146

Subependymal giant cell tumors in tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.146

Subependymal giant cell astrocytoma (SEGA): Is it an astrocytoma? Morphological, immunohistochemical and ultrastructural study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.146

Prevalence of subependymal giant cell tumors in patients with tuberous sclerosis and a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.146

The TSC1-TSC2 complex: a molecular switchboard controlling cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.146

Linkage of an important gene locus for tuberous sclerosis to a chromosome 16 marker for polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.146

Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.146

Identification and characterization of the tuberous sclerosis gene on chromosome 16

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.146

Possible mechanisms of disease development in tuberous sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.146

Surgical treatment of intraventricular tumors associated with tuberous sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.146

Outcomes of resecting subependymal giant cell astrocytoma (SEGA) among patients with SEGA-related tuberous sclerosis complex: a national claims database analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.146

Surgical resection of subependymal giant cell astrocytomas (SEGAs) and changes in SEGA-related conditions: a US national claims database study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.146

Rapamycin causes regression of astrocytomas in tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.146

Regression of subependymal giant cell astrocytoma with rapamycin in tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.146

Molecular activity of sirolimus and its possible application in tuberous sclerosis treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.146

Research and innovation in the development of everolimus for oncology.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.146

Clinical pharmacokinetics of everolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.146

Rapamycin passes the torch: a new generation of mTOR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.146

Effect of rifampin on apparent clearance of everolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.146

Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.146

mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.146

The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.146

Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.146

Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.146

Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.146

Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.146

Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.146

Everolimus alters white matter diffusion in tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.146

Regression of subependymal giant cell astrocytomas with RAD001 (Everolimus) in tuberous sclerosis complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.146

Effective everolimus treatment of inoperable, life-threatening subependymal giant cell astrocytoma and intractable epilepsy in a patient with tuberous sclerosis complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.146

Testosterone concentrations and sirolimus in male renal transplant patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.146

Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.146

21 January 2018

Identifiers

DOI

10.2217/FON.12.146

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23231513%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference